Back to Agenda
Session 3: Data Sources
Session Chair(s)
Michael Lees, MA
Chief Operating Officer and Head of Market Access Strategy
PHMR Ltd, United Kingdom
As the importance of real world evidence to healthcare decision makers continues to grow, so do the questions addressed by real world evidence and the sources of such evidence. In addition to the various sources of claims data and data from health records in North America, EU and Asia, the number of registries developed to shed further light on disease management, outcomes and real world effectiveness continues to grow, while data captured from less traditional sources such as early access programs and social media is also increasingly used. This session aims to identify the emerging trends when making the choice about the most appropriate choices for the sources of real world evidence from the perspective of HTA bodies, real world evidence practitioners and pharmaceutical industry.
Speaker(s)
Insights from a RWE Practitioner
Cormac Sammon, PhD
PHMR, United Kingdom
Chief Epidemiologist and Head of RWE
The Industry (Medical Affairs) Perspective
Antonia Electra Panayi, PhD, MSc
Takeda, United States
Head, Global Medical Evidence
The Access Perspective
Amr Makady, PharmD, PhD, MSc
Johnson & Johnson, Netherlands
Health Economics and Market Access Manager
Panel Discussion with Q&A, Moderated by:
Michael Lees, MA
PHMR Ltd, United Kingdom
Chief Operating Officer and Head of Market Access Strategy
Have an account?